Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
May 10, 2022
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Amanda, and I'll be serving as your conference operator for today. I'd like to welcome all of you to the Cronos Group 2022 First Quarter Earnings Conference Call. This call is being recorded today. At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Please go ahead.
Shayne Laidlaw
executiveThanks, Amanda, and thanks to everyone for being with us today as we go over Cronos Group's financial and business results for the first quarter of 2022. With me on the call are Mike Gorenstein, our Chairman, President and CEO, and Bob Madore, our CFO. This morning Cronos Group put out a news release with these financial results, and it's been filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be posted on our website in the Investor Relations section. Before handing the call to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from what the forward-looking statements project. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and in our SEC filings, which are available on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Details about non-GAAP financial measures, including reconciliations to US GAAP, can also be found in the earnings materials available on our website.
Shayne Laidlaw
executiveWe're going to give our prepared remarks at this point, and after that we'll open things up for a question-and-answer session. So with that, I'll hand things over to the Chairman, President and CEO of Cronos Group, Mike Gorenstein.
Mike Gorenstein
executiveThank you, Shayne. I’m not sure whether all of you missed me to the same degree that I’ve missed everyone here. But given that this is a one-way line, I’ll simply get started right away. The reason I founded Cronos was the opportunity, which comes along once in a lifetime, to help build and shape an industry. That industry has the potential to improve countless lives. In my role as CEO, I’m committed to restoring a startup culture and a founder’s mentality throughout every level of the organization. I want to express thanks to our dedicated employees, who have worked very hard and who continue to bring their passion for the industry and for Cronos with them to work each day while we navigate our strategic realignment. We have established a strong foundation for ourselves. Much more work lies ahead of us, and we will keep executing our vision. Because this is my first call back in the role of CEO, I’ll begin by explaining Cronos’s strategy. After that, I’ll lay out my four immediate priorities, and I’ll close with some detail on our encouraging results for this quarter. As legalization of the cannabis industry continues to evolve, it presents many opportunities for value creation across different verticals, including agriculture, ingredient supply, branded products, distribution and retail. Although many of the best-known cannabis companies are known for following an asset-heavy, vertically integrated model, Cronos takes a different approach.
Mike Gorenstein
executiveOur view is that putting all our resources behind becoming the top branded products company will let us win with consumers against firms that attempt to serve every need for everybody. The cannabis sector offers ample opportunity to generate enormous shareholder value by succeeding in just one vertical, and branded cannabinoid products are the one we chose. Seven years ago, when I founded Cronos, I selected Canada since it was the earliest market with federal legality. That gave us a unique chance to build intellectual property, assemble a lead team, and eventually hold a leading branded portfolio of disruptive products without borders that we can launch in other markets, such as the U.S., once they open up. Our strategy remains the same today. And as I will cover later, we are beginning to witness the results from consumers in Canada and Israel. Making an iconic branded cannabinoid product means recognizing a consumer need and creating a product that satisfies it. As with other consumer products, cannabinoid products stand apart through taste, aroma, appearance, the look and feel of the product, and the brand's story. Yet maybe the most crucial differentiator for us is the effect. More than 100 distinct cannabinoids exist that, alone and together, produce differing effects, and we keep pushing forward a disruptive platform capable of delivering differentiated experiences, using rare cannabinoids via custom-tailored delivery systems, that please consumers in ways legacy cannabis products did not.
Mike Gorenstein
executiveWe recognize that succeeding in the brand and product vertical isn't easy, and I want to tackle that directly. Every mature legal market has intense competition, and the illicit market is very resilient, yet most rivals concentrate on price instead of quality and differentiation. As a legal cannabinoid company in North America, we hold a natural cost edge over the illicit market thanks to the tax and regulatory framework. We also possess a distinctive advantage for delivering iconic brands and products, since our resources let us think long-term and innovate—which is why taking the time to craft the best products matters so much, as it lets us win on quality instead of joining a race to the bottom. We believe better will be first, and we've witnessed that through how our leading borderless innovations perform in today's market, such as SOURZ by Spinach and Spinach FEELZ. We also believe these superior borderless products are winning with consumers in other markets too. Now that the Cronos identity and strategy have been level set, I want to talk about my four key priorities.
Mike Gorenstein
executiveTo start, we're going to deliver growth that's margin accretive, with our attention on adult-use products. When I was CEO previously, what you mostly heard from me was a focus on constructing our platform, conducting research, and developing a strong lineup of branded products. Now, following years of hard work and investment, we have a solid platform, strong institutional knowledge regarding what consumers are looking for and what cannabinoids are capable of, and excellent branded products reaching the market. My top priority is proving out the Cronos investment thesis by delivering top line growth. Our aim is to outgrow the industry in Canada and Israel alike, and I want to ensure that our growth happens the right way, which means growth that is margin accretive. I've spoken before about being fine with higher OpEx and variable costs early in our product launch cycle in order to prove out demand and reach critical mass. Given the results we've been seeing from our products that are in end markets today, we can begin concentrating on improving margins. Next, greater operational efficiencies, disciplined expense management, and leading a successful transition away from our Peace Naturals Campus toward a more agile supply chain — our business model was never to be the pharma. Winding down operations at our Peace Naturals Campus brings us further in line with our priorities and our focus on brands and R&D.
Mike Gorenstein
executiveAt this point, we're confident that the industry and our Canadian supply chain have reached a maturity level that lets us put this approach into practice. The Peace Naturals Campus is the place where everything started for us. So for me personally, the closure is a sad moment. I'd like to pause and acknowledge what the team members there have contributed. Without their hard work and dedication, we wouldn't be where we are today, and we will always regard them as part of the Cronos family. Getting our supply chain optimized is a strong first step, but I want to be sure we return to running like a lean, scrappy startup. So we'll keep evaluating our cost structure across every area of the business. Third, we're focusing investments on the opportunities with the highest returns, specifically borderless investments. We'll keep investing in our innovation pipeline so we can bring consumers the products they want, along with novel products that can surprise and delight. Having superior branded products that we can consistently replicate, produce, and distribute across multiple jurisdictions as they open up in the future matters to us. Through our Spinach brand, we're creating borderless innovation that we test, learn from, and improve in the Canadian market.
Mike Gorenstein
executiveSpinach's success demonstrates that our fundamentals are sound, and having our borderless products win in Canada is among the strongest ways to get ready for legalization in other markets. We're also eager to keep pushing rare cannabinoid development and commercialization forward. Rare cannabinoids let us set our products apart by delivering unique effects that address specific consumer needs. Launching Spinach FEELZ, our rare cannabinoid sub-brand — a platform built to deliver unique and enhanced experiences made possible through a proprietary blend of rare cannabinoids — is a prime example of a borderless product. Our cultured CBG gummy and vape lineup is performing well in market, and we're only getting started. I want our company to be mission ready to execute on bringing our amazing borderless products to new markets with speed and efficiency. And we have a very exciting innovation pipeline to execute on. And last but certainly not least, positioning Cronos to ultimately win in the U.S. Cannabis market. We bring most of our adult use products to consumers in Canada, but we keep conducting extensive consumer insight work across all the regions where we operate, with a specific focus on the adult use market in the U.S.
Mike Gorenstein
executiveThe U.S. is still an excellent market for gaining deeper insight into how consumer tastes evolve, and meanwhile we concentrate on building approaches and strategies that win in the markets where we currently operate. While I was serving as Executive Chairman, my focus was on evaluating opportunities in the U.S. Our deal with PharmaCann created a strong foundation for entering the U.S., and we will keep cultivating potential strategic relationships that we expect will make adult use success possible in the U.S. Given our evolving product portfolio and the most robust balance sheet in cannabis, I believe we are in a solid position to pursue the branded cannabinoid product opportunity in the U.S., through organic product development as well as disciplined and opportunistic M&A. Moving to our results, I want to call out the progress in our Rest of World segment, which is led by strong performance in Canada and Israel alike. First, in Canada, we keep streamlining our branded adult use portfolio so that it centers on Spinach, and we keep growing market share organically across Canada. According to Hyfire data in the first quarter of 2022, Spinach held an approximate 17% market share in the gummies category. All three original SOURZ by Spinach gummies ranked in the top 10 for market share in Canada.
Mike Gorenstein
executiveBack in March, we introduced Cherry Lime — the fourth flavor under SOURZ by Spinach — and it's already moving up the market share rankings fast. Since our first gummy hit the market in July 2021, how quickly consumers have taken to SOURZ proves our belief that being first isn't necessarily best, and it shows how well we execute on delivering differentiated borderless products. We keep strengthening the Spinach flower lineup to satisfy consumer appetite for larger formats without any drop-off in quality. Wedding cake just recently launched, and we'll keep rolling out those strain specific, large format SKUs that are so highly sought after. What's driving our growth is branded product, not a value offering that serves as an outlet for lower quality flower. Our wins in the flower category come after years of genetic green work, which is what lets us now bring these great strains to market. Much like the agriculture market, we believe the long-term value created in flower will mostly stem from breeding proprietary genetics, and based on what our success in Israel has shown us, that's the best path to creating successful borderless flower products. Vapes is a space where our goal isn't merely to compete — we want to win. After moving to one brand formats and launching our CBG vape, we're beginning to see market share pick up in that category.
Mike Gorenstein
executiveBased on Hyfire's data, our Spinach vape lineup broke into the top 10 by market share in Ontario during April. With that milestone behind us, we're bringing out new vape offerings in May, and also in Alberta, BC and Manitoba — among them Cosmic Green Apple and Polar Mint Vortex — as we work to keep growing our share of the national category. Pre-rolls are another category we believe we can win. Over the longer term, we see pre-rolls growing in importance, and we think there's substantial room to stand apart. As with gummies, being first to market isn't necessary for us. Our goal is to be the best. Several projects in this category are underway, and we look forward to sharing further updates when the timing is right. Now I'd like to discuss one of the most under-appreciated parts of the Cronos story: Israel. Israel stands as the strongest illustration of how fast the cannabis sector can realize its potential when the regulatory framework is right. The Israeli cannabis regulator, the Yakar, has done an excellent job establishing a framework that gives patients superior access to cannabis while also creating a strong opportunity for sustainable industry growth. For Cronos, Israel represents a chance to place excess supply from Canada.
Mike Gorenstein
executiveFor us, it’s a key market to provide branded products that satisfy what our consumers need. We had faith in Israel and put money in early, back in 2017, and we have people on the ground there actively making and selling Peace Naturals products. Our solid standing in Israel has helped Cronos become recognized in the market that shapes the operators and consumers. And it led us to reaching a top three market share. Those efforts produced revenue in Israel of $9.1 million in the first quarter, roughly 90% higher than the fourth quarter of '21 and about 260% above the first quarter of '21. Our results came against an overall Israeli market that saw roughly 40% year-over-year growth and key <<inaudible>> sold in the first quarter. We’re confident there’s a long runway of growth ahead for us in Israel, both with the products we already have in market and the chance to launch additional borderless products. As a reminder, we began this year by carrying out a realignment of the business to better position Cronos to drive profitable and sustainable long-term growth. This realignment places our brands and products at the center. We announced two main changes to the organizational structure.
Mike Gorenstein
executiveTo start, we brought functions together beneath shared leadership, and that is already paying off through lower costs and quicker choices. Next, we revealed plans to leave our Peace Naturals site in Stayne as part of pushing further toward an asset-light model, with a big share of Canadian manufacturing shifting to Cronos GrowCo even as we keep other third-party manufacturing ties in place. We are moving quickly to construct our own area inside GrowCo so it can meet our future requirements. We could not be happier with GrowCo's cultivation work and we keep buying premium dried flower from that operation. This represents a landmark moment in how our supply chain has developed, and you can see part of the favorable COGS reflected in the margin, which Bob will discuss in more detail when he speaks. At a high level, we can obtain top-quality flower at GrowCo for below what cultivating it ourselves at the Peace Naturals site used to cost, and because we hold 50% of the equity as well, there is extra benefit from the margin gains produced by the move to GrowCo that will appear in the bottom-line contribution. GrowCo amounted to more than merely one piece of our supply chain.
Mike Gorenstein
executiveThis asset is one whose worth has gone underappreciated, and there's hidden value in it. GrowCo truly is only at the beginning. While we are their biggest customer, when you take out what we bought, they still brought in roughly $7 million this quarter from customers other than Cronos. Considering how GrowCo is performing now and what's expected of them, we feel confident about the roughly $97 million senior secured loan in total that we extended to GrowCo and to Mucci's back in 2019. And GrowCo has begun paying back that loan, which only makes stronger our already industry-leading balance sheet of about $1 billion in cash and short-term investments. Moving to appointments in the organization, I'm pleased to share that Terry Doucet has been named General Counsel, having filled the role on an interim basis since December '21. Terry joined Cronos in 2018 and has been a key figure in helping build the organization into what it is today. Over the past few years, Terry has steered Cronos through substantial growth, including building out our legal and regulatory affairs teams, our strategic investment from Altria, our Ginkgo collaboration, our investment in PharmaCann and our numerous product commercialization initiatives. As we restructured the organization to align with our go-forward strategy, our main focus will remain on elevating our brand through borderless innovation that can be rolled out in new markets.
Mike Gorenstein
executiveHaving said that, I'll now hand things over to Bob so he can walk you through our financials.
Bob Madore
executiveThanks, Mike, and good morning everyone. For the first quarter of 2022, the company reported consolidated net revenue of $25 million, an increase of 99% compared with the first quarter of 2021. The year-over-year revenue growth came mainly from higher net revenue in the Rest of the World segment, which was driven by growth in the Israeli medical market and the Canadian adult use market. Consolidated gross profit in the first quarter of '22 was $6.9 million, which represents a $9.9 million improvement over the first quarter of 2021. Gross margin was positive at 28%, up from negative minus 23% last year. The improvement versus the prior year came primarily from increased gross profit in the Rest of the World segment, which I'll cover in a bit more detail shortly. Consolidated adjusted EBITDA for the first quarter of 2022 was negative $18.9 million, representing a $17.7 million improvement from the first quarter of 2021. This improvement versus the prior year was driven primarily by better gross profit and by a decline in sales and marketing and research and development expenses in connection with our strategic realignment plan. Turning to our reporting segments, in the Rest of the World segment, we reported net revenue of $22.7 million in the first quarter of 2022, an increase of 123% from the first quarter of 2021.
Bob Madore
executiveThe year-over-year revenue increase came mainly from growth in Israel, which rose 263% compared with a year earlier, largely due to the cannabis flower category, along with growth in Canada, which climbed 79% year-over-year, driven by our cannabis extracts category, which we expect to get a boost from launching our gummies platform, which wasn't around in the prior year, plus the launch of a one-gram date that delivers strong value to the consumer. For the first quarter of 2022, gross profit in the Rest of the World segment reached $6.7 million, an improvement of $10.8 million over the first quarter of 2021. Gross margin was positive at plus 30%, up from a negative minus 41% last year. The gain compared with the prior year stemmed mainly from higher cannabis flower revenue, the launch of additional cannabis extract products that generally carry a higher gross profit margin than other product categories, lower inventory valuation adjustments, and lower depreciation expense resulting from the lower fair value of our Peace Naturals Campus, which relates to the impairment we recorded in Q4 tied to our restructuring plan, and finally, we saw lower cannabis biomass costs as we start to further leverage our joint venture arrangement with GrowCo, which, as Mike just noted, has been very successful so far.
Bob Madore
executiveWe feel really good about that result. For the Rest of the World segment, adjusted EBITDA came in at negative $3.4 million in the first quarter of 2022, which is an $18.8 million improvement over the first quarter of last year. That gain compared with the prior year came mainly from the gross profit improvement we discussed, along with lower sales and marketing costs and reduced research and development expenses tied to our strategic realignment. Now moving to the US segment, net revenue for the first quarter of 2022 came in at $2.3 million, a 5% decline versus the first quarter of 2021; that year-over-year drop was driven mainly by lower volumes resulting from reduced promotional spend as the company works through its review of the US business as part of the strategic realignment. Gross profit in the US segment for the first quarter of 2022 was $200,000, which is a $1 million decline from the first quarter of 2021. Gross margin was a positive 9%, down from a positive 48% last year. That year-over-year decline was primarily attributable to higher inventory valuation adjustments, increased shipping costs and an unfavorable sales mix. Adjusted EBITDA for the US segment in the first quarter of 2022 was negative $7.1 million, an improvement of $2.4 million from the first quarter of 2021.
Bob Madore
executiveThat improvement over the prior year came mainly from lower sales and marketing research and development expenses, as we noted earlier in connection with our strategic realignment plan. Now on the balance sheet: the company finished the quarter with roughly $1 billion in cash and short-term investments, which is down about $23 million from the fourth quarter of 2021. Capital expenditures during the quarter totaled $700,000, a 90% decrease year-over-year, driven mainly by reduced spending on property plant equipment across our facilities in the Rest of the World segment. We stay committed to deploying capital in a very disciplined manner and only in ways that align with our strategic priorities and return requirements. With that, I'll hand it back to Mike.
Mike Gorenstein
executiveThanks, Bob. We have complete faith in our team, in the plan we're following, and in what lies ahead, and I'm eager to continue collaborating with our gifted colleagues as we build out our highly differentiated branded cannabinoid platform and generate value over the long term. In summary, this quarter's results leave me pleased. Our gummies are plainly a consumer favorite, reaching the top of the charts in Canada; we are executing in Israel and generating robust revenue growth; and we are making excellent progress on strengthening the margin profile of our business. I look forward to a future in which people across the globe can enjoy our next-generation cannabinoid products. With that, I'll open the line for questions.
Operator
operatorOur opening question is from Michael Freeman at Raymond James. Your line is open now.
Michael Freeman
analystWe really appreciate you taking our questions. We’ll follow up with you, Mike, and thank you. It’s good to see you, Bob and Shayne. Congratulations on this quarter. The way the business is evolving is starting to become really visible to us, so congratulations on that. My first question concerns the shift from Peace Naturals Campus to GrowCo. I’m pleased to hear the transition is going smoothly and that you’re seeing a COGS benefit from it. Could you describe, I suppose, what share of Cronos’s biomass currently comes from GrowCo as opposed to wholesale or contract growers?
Bob Madore
executiveYeah. So during this quarter, we actually bought roughly $3 million in biomass from GrowCo. That figure is going to keep rising as demand justifies it. We're currently winding down our stain or transition, right? So we're completing our final cultivation and harvest, and we'll wrap up production of that product, et cetera, while we ramp up GrowCo at the same time. And we think a major gross margin opportunity ahead of us is really capitalizing on the GrowCo relationship and the economics surrounding biomass cultivation, which makes up a big percentage of what we do and what we sell. But there's more to come on that, and we expect it to be a larger component of our gross margin improvement going forward.
Michael Freeman
analystOkay, thanks Bob — that's genuinely useful. So here's a follow-up question. From what we've seen while covering Ginkgo Bioworks, it's clear you already have CBG available commercially. Ginkgo has supplied you with a CBG VA producing microbe. I'd like to ask whether you can update us on how things are going in those rare cultured cannabinoid segments. Also, how do you see this fitting into Cronos's borderless IP strategy? And are there any extra considerations when it comes to exporting these specific cannabinoids? Thank you.
Mike Gorenstein
executiveAbsolutely, thank you. So, looking at the situation right now, CBG is doing quite well, and it's still early days, but for that single SKU under SOURZ — apologies, I mean FEELZ — we captured 2.5% market share. The traction we're getting with the CBG vapes is excellent. What we're finding is that when we bring rare cannabinoids into some of the delivery systems already on the market, they perform strongly, and we view them as additive rather than cannibalistic. I'd also say we're making really solid progress when it comes to incorporating new cannabinoids into our platform. And I believe you'll see new cannabinoids launched this year. So we're genuinely excited about not just rolling CBG out in other product formats, but also new cannabinoid combinations across different formats. Now, regarding borderless products — the way we see it, there are two components involved there. First, there are delivery systems, which could be something like the gummy platform. We'll be launching a number of other truly disruptive delivery systems, and then second, there's the actual blend of cannabinoids, and that's precisely where the rare cannabinoids fit in. So in our view, that really reaches every part of our borderless products — with the sole exception being dry flower.
Mike Gorenstein
executiveStill, we're genuinely enthusiastic, and we believe placing them into additional markets that are federally legal won't pose a problem as those markets begin to open. So that ranks among the most thrilling developments we have ahead of us across the coming 1 to 2 years.
Operator
operatorJohn Zamparo of CIBC has our next question, and his line is open now.
John Zamparo
analystMorning, and welcome back, Mike. I'd like to begin with Israel. The top line figure for the quarter there was remarkable. I'm hoping to get a sense of how repeatable this kind of result is — and I assume you'd prefer we not treat it as a baseline for quarters ahead, but I'd just like some sense of how much volatility you anticipate in Israel's results over the coming quarters.
Mike Gorenstein
executiveAbsolutely. Thanks for that — it's a really good question. And just to remind everyone, if you compare how we operate in Israel with what some of our competitors do, this is not a lumpy B2B wholesale kind of transaction. What really drives it is branded sales that we make through pharmacies. So we do see it as consistent. We've been anticipating growth for a good while now, and Israel is a fantastic market. I think our brand has been extremely well received. We have a strong team that's moving things forward. So we're quite optimistic about what's ahead in Israel, and we don't view things as lumpy. We believe there are further opportunities as the market keeps growing — both from the products we already have on the market and from being able to launch additional products there — but we see a great opportunity, particularly given the fact that we aren't competing in the illicit market the way we do in North America.
John Zamparo
analystAll right, that helps a lot, thanks. Then, to follow up on the CBG side: it really does look like these products are getting a strong reception, on both the gummies and the vapes. I'm curious whether you have any data or insight into how much of that comes from the novelty of these products — which I think does exist to some degree — as opposed to repeat purchases. Is there anything you can share on that?
Mike Gorenstein
executiveYeah, I believe you receive plenty of strong responses regarding the real experiences that either you or consumers are having with the CBG products. So we don’t view it as just a novelty or a trial. I think when we receive that kind of feedback — and we did receive it from consumers or from the insight work we conducted early on — we genuinely expect this to be, again, something additive and something where we see further growth, and we believe there is more ahead with certain other cannabinoids too.
Operator
operatorWe’ll take our next question from Andrew Carter with Stifel. Your line is open now.
Andrew Carter
analystThank you. Good morning. For my first question, I'd like to ask about the Canadian shipments. They appear to have declined 24% quarter over quarter. According to our headset data, your consumption fell 12%. So I suppose you could give us some detail on that — I know you — was there any COVID discontinuation there, was pricing a factor, and is any inventory reduction happening at the province level? Thanks.
Bob Madore
executiveOh, please, Mike, go right ahead—yes.
Mike Gorenstein
executiveYeah, so to kick things off, I think when you look at Q4 to Q1, seasonality is definitely there, and we observe it annually. Year-over-year, a lot of improvement was visible, though some of that was certainly present across the industry. One thing we're glad about — call it a silver lining — is that we still gained market share during the quarter, but we believe there are plenty of extra levers available for us to pull so that revenue keeps growing, not only market share. So I'll hand it to Bob for some of the other nuances.
Bob Madore
executiveWell, no — another encouraging sign is that a number of the new products we launched ended up becoming real hero SKUs for us when all was said and done, especially quite a few items in our SOURZ line, which joined other new product innovations, and with the margin increase in the quarter, it's simply an evolution of how we see the opportunity ahead, right? Not only in Canada, but for the rest of the world in the business overall. So Mike pointed out some of the seasonality between Q4 and Q1 in Canada specifically, but what we've observed, particularly as Mike noted with market share gains, is extremely encouraging, and the fact that the business was up the way it was in the quarter is encouraging, and pairing that with the margin improvement, we feel like we're really moving this business in the right direction, in line with the strategy that has been pretty consistent. Right? So we're excited about it.
Andrew Carter
analystYeah, I get the seasonality point, which is exactly why I led with consumption being down 12%. What I'm asking about is shipments, which fell 24%. To be specific, I'm seeing extracts up 5% and your edibles up 15% sequentially. So is the issue whether you're capturing your fair share of shipments at the provincial level, or have they already placed their orders? And my guess is that given how well Spinach is performing, there's likely a provincial inventory shortfall, and you may be looking to raise it — anything you can give me on that front would help.
Mike Gorenstein
executiveYes. And I think at times you do notice some lumpiness in the way the provinces place orders. Our relationships with retailers are strong, and I think what matters most is making sure retailers are pulling through and selling, and when you see that, I think it sort of normalizes how the provinces have done the ordering afterward. So I think we're seeing things pick up, especially toward the end of the quarter, and we believe that progress should continue going forward.
Andrew Carter
analystAnd that's my final question for today. You brought up evaluating the US CBD business, and I'm seeing what looks like roughly $11 million in cost for the quarter. How does that play out with Altria going forward — I mean, given the current environment, with only quality federal legality being pursued, do you all still see a chance to collaborate under these conditions, or does this evaluation simply mean, "Hey, we may not be able to create value here, so let's just preserve resources for full THC"? Thanks.
Mike Gorenstein
executiveYeah, I think — look, having Altria as a partner is a really powerful tool, and they're a great one. And I think the way we approach it is very aligned. If there's no opportunity to create value, I don't think either of us would push it. What we want is to be sure we've got a product offering that consumers genuinely want before we switch on the kind of distribution they have. So we're assessing all sorts of things, different products. I think when we looked at what we did in Canada to get back to growth, much of that came down to concentrating on a few core hero SKUs that strengthened things, plus looking at rare cannabinoids as a driver. So those will be some of the levers we look to pull. We're definitely focused on some bottom line optimization, particularly in this environment. So that will factor in, but we have a fairly similar view. Ultimately, we want to make sure that anything we do for topline growth ends up being margin accretive.
Operator
operatorMatt Bottomley from Canaccord has the next question — your line is open now.
Matt Bottomley
analystYes, good morning. Glad to be back, Mike, and thanks for taking the questions. I was hoping you could give us a somewhat higher-level picture of where the international opportunities for Cronos are headed. Israel appears to be progressing nicely, as a couple of other public companies seem to be gaining ground as that country potentially moves toward full adult utilization. I'm just wondering whether you could address other market opportunities that might enter the picture over the next 12 months, along with your prospects for adult use in Israel.
Mike Gorenstein
executiveSure. One key takeaway for us has been how crucial it is to stay focused and make sure we're going into the right markets. We still have a presence in Germany, and as we look at opportunities that may open up, I wouldn't necessarily call it a chance to enter adult use within the next 12 months, but we do know new legislation is beginning to take shape. So wherever we go, given the cost and time involved, we want to be sure it's something genuinely exciting and that we can ultimately start achieving the results we're getting in Israel. So I'd put Germany near the top of the list. But we aren't really chasing some of the smaller medical opportunities that we don't see translating into adult use formats. We do believe many of the medical markets are sort of at the start of a transition to adult use once you begin to see upside. So I would highlight Germany. We certainly keep an eye on a number of other markets and remain optimistic, but a lot is moving in the world, especially in Europe right now, that can tend to derail some of that progress, so we'll be cautious.
Mike Gorenstein
executiveRegarding Israel, what's interesting is that everybody asks about adult use, and we do believe that will happen at some point, but we don't need adult use to keep seeing sustainable and really durable growth there. So I think there's a lot of runway in the medical market over the next year or two years. We know there's been a lot of discussion and a lot of excitement for adult use both from consumers and from regulators. So I wouldn't expect it in '22. I do think it's on the horizon, but I don't think that should slow down our growth there.
Matt Bottomley
analystAll right, got it. And maybe one quick follow-up on how the company thinks about putting capital to work, or making strategic investments across different markets. Obviously, you’re holding a pretty sizable amount of cash, and when you consider what THC exposure in the US could mean for Cronos, that might be a year off — or honestly, who knows, it could be three or four years away. So how do you weigh keeping those cash reserves in place for what could be the big win from US THC against perhaps making inroads into some of these other markets that get fewer headlines but are beginning to open up outside North America?
Mike Gorenstein
executiveYes, I believe that's an excellent question. Broadly speaking, you need to consider where things are headed over the long term — whether that's the US or a market within the EU — and I genuinely believe branded products are what will matter. So it really hinges on how the market develops and how we choose to invest. At the end of the day, the single most important thing we can do is hold the strongest branded product portfolio, and that's the lens through which we consider borderless investments — putting that capital in now and getting the product offering right. That positions us to enter a market and deliver those products to consumers. When markets open up, we will win in them. Now, that could require extra investment in either manufacturing or distribution, depending on how the market and regulations are structured, and that's largely what the capital we deploy is for. But you're right — there will be an assessment of whether it makes sense to employ capital in the US or other markets. I do think our balance sheet gives us optionality, so it isn't necessarily an either-or; it's simply asking what the ROI on the investment is. But when we look at the US from a velocity standpoint, we aren't going to be seeking to buy licenses or merely asking how many licenses exist in X state and what the math says — it's about making sure we simply have the chance to get our products and our brand in front of consumers, and we also identify brands that are performing well and that add to our portfolio.
Mike Gorenstein
executiveThat's an area we'll be looking at for investment or acquisition. But I'd say the approach there differs somewhat from what most of the prominent US investments you hear about look like, and I think as supply begins catching up with demand over the next several quarters, and a lot of the limited likely to states that it will also turn into a branded game.
Operator
operatorWe move to our next question, coming from Gaurav Jain at Barclays. Your line is open now.
Gaurav Jain
analystI apologize if someone has already raised this, but your EBITDA loss for this quarter is likely the smallest it has been in quite a while — possibly ever. So should we take this as the new run rate, given that Israeli revenues are going to keep coming in on a steady basis, as was mentioned earlier? That is my first question.
Mike Gorenstein
executiveApologies, Gaurav — your audio faded in and out there, so could you say your question again, please?
Gaurav Jain
analystSure, and sorry about that. So my question is about the $18 million EBITDA loss you reported for Q1 — is that a fair run rate to use for the remaining three quarters?
Mike Gorenstein
executiveWe won't be providing guidance on the EBITDA run rate going forward. Right now, we're generally just not giving guidance. That said, we have quite a few cost savings programs in place that haven't fully kicked in yet, and we expect them to start showing up in the back half of the year. This is something we're very focused on—not only regarding what we've announced, but also additional cost saving initiatives. So that's a key focus. You can expect us to put in a lot of work and for the trend of continued EBITDA improvement to carry on.
Gaurav Jain
analystSure. Thanks. My second question concerns the share price and its current level, and the Company's EV is roughly the same as the cash balance shown on the balance sheet. So is there a way for you to put the cash flows to work along with share repurchases, or is that something you wouldn't consider.
Mike Gorenstein
executiveHonestly, what I'm really concentrating on at this moment is doing everything possible to strengthen the fundamentals of the business and to ensure we're positioned for future growth. My view is that if we accomplish that, the share price generally tends to follow — but the priority today is genuinely the business and how it's performing in the end market, and hopefully all the analysts on this call can help get that message across to the stock market so it follows along.
Operator
operatorAt this point, I see no additional questions. That brings today's conference call to an end. We appreciate everyone joining us. You're free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.